From: Oxidative stress in prostate hyperplasia and carcinogenesis
Gene | Gene name | Location | Papers |
---|---|---|---|
KLK3 | Kallikrein-related peptidase 3 | 19q13.41 | 3000 |
AR | Androgen receptor | Xq12 | 1221 |
MKI67 | Marker of proliferation Ki-67 | 10q26.2 | 424 |
PTEN | Phosphatase and tensin homolog | 10q23.3 | 376 |
TP53 | Tumor protein p53 | 17p13.1 | 343 |
TMPRSS2 | Transmembrane protease, serine 2 | 21q22.3 | 336 |
CTNNB1 | Catenin (cadherin-associated protein), beta 1 | 3p21 | 312 |
BRCA1 | Breast cancer 1, early onset | 17q21 | 178 |
BRCA2 | Breast cancer 2, early onset | 13q12.3 | 156 |
PROC | Protein C (inactivator of coagulation factors Va and VIIIa) | 2q13-q14 | 135 |
CDKN1A | Cyclin-dependent kinase inhibitor 1A (p21, Cip1) | 6p21.2 | 125 |
NKX3-1 | NK3 homeobox 1 | 8p21.2 | 120 |
SRD5A2 | Steroid-5-alpha-reductase, | 2p23 | 120 |
SRC | SRC proto-oncogene, non-receptor tyrosine kinase | 20q12-q13 | 97 |
KITLG | KIT ligand | 12q22 | 93 |
CDKN1B | Cyclin-dependent kinase inhibitor 1B (p27, Kip1) | 12p13.1-p12 | 92 |
CD44 | CD44 molecule (Indian blood group) | 11p13 | 87 |
TGFB1 | Transforming growth factor, beta 1 | 19q13.1 | 83 |
HIF1A | Hypoxia inducible factor 1, alpha subunit (basic helix-loop-helix transcription factor) | 14q23.2 | 82 |
CYP17A1 | Cytochrome P450, family 17, subfamily A, polypeptide 1 | 10q24.3 | 82 |
PTGS2 | Prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) | 1q25.2-q25.3 | 81 |
PPARG | Peroxisome proliferator-activated receptor gamma | 3p25 | 81 |
PCA3 | Prostate cancer associated 3 (non-protein coding) | 9q21.2 | 78 |
IGFBP3 | Insulin-like growth factor binding protein 3 | 7p12.3 | 76 |
EZH2 | Enhancer of zeste 2 polycomb repressive complex 2 subunit | 7q35-q36 | 75 |
ETV1 | ETS (E twenty-six) variant 1 | 7p21.3 | 73 |
GSTM1 | Glutathione S-transferase mu 1 | 1p13.3 | 72 |
JUN | Jun proto-oncogene | 1p32-p31 | 65 |
CAMP | Cathelicidin antimicrobial peptide | 3p21.3 | 61 |
ELAC2 | ElaC ribonuclease Z 2 | 17p11.2 | 56 |
SERPINB5 | Serpin peptidase inhibitor, clade B (ovalbumin), member 5 | 18q21.33 | 54 |
CD82 | CD82 molecule | 11p11.2 | 50 |
AMACR | Alpha-methylacyl-CoA racemase | 5p13 | 50 |
IGF1R | Insulin-like growth factor 1 receptor | 15q26.3 | 49 |
IL10 | Interleukin 10 | 1q31-q32 | 47 |
E2F1 | E2F transcription factor 1 | 20q11.2 | 46 |
MSMB | Microseminoprotein, beta- (10q11.2) | 10q11.2 | 45 |
TRPM2 | Transient receptor potential cation channel, subfamily M, member 2 | 21q22.3 | 44 |
CYP3A4 | Cytochrome P450, family 3, subfamily A, polypeptide 4 | 7q21.1 | 43 |
CLU | Clusterin | 8p21-p12 | 43 |
PSCA | Prostate stem cell antigen | 8q24.2 | 42 |
FOS | FBJ murine osteosarcoma viral oncogene homolog | 14q24.3 | 42 |
CASP9 | Cysteine-aspartic acid protease (caspase) 9, apoptosis-related cysteine peptidase | 1p36.21 | 40 |
VEGFA | Vascular endothelial growth factor A | 6p12 | 40 |
FOXA1 | Forkhead box A1 | 14q21.1 | 40 |
MET | MET proto-oncogene, receptor tyrosine kinase | 7q31 | 40 |
CYP3A5 | Cytochrome P450, family 3, subfamily A, polypeptide 5 | 7q21.1 | 39 |
RASSF1 | Ras association (RalGDS/AF-6) domain family member 1 | 3p21.3 | 39 |
PDLIM4 | PDZ and LIM domain 4 | 5q31.1 | 38 |
MSR1 | Macrophage scavenger receptor 1 | 8p22 | 38 |